FOLR1 and adenocarcinoma: In adenocarcinoma patients, the detection rate was 54.55% (18/33) and 75.75% (25/33) for anti-EpCAM-MNs or a combination of anti-EpCAM-MNs and anti-FRα-MNs, and a significant improvement in enrichment efficiency was obtained with a combination of anti-EpCAM-MNs and anti-FRα-MNs (p = 0.001).